About Us
Our Company
MingSight Pharmaceuticals is a clinical stage company focused on the development of a new generation of selective inhibitors of protein kinase C (PKC) for the treatment of diseases with high unmet medical needs.
MS-553, A New Generation, Potent and Selective PKC Inhibitor
Major improvements in selectivity, safety and PK enable MS-553 to address the significant shortcomings seen with previous pan-PKC inhibitors.
Ophthalmology: Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
MS-553 is an orally administered and highly selective protein kinase C (PKC) inhibitor. It has a potential to become a non-invasive and efficacious therapy for diabetic macular edema (DME) and diabetic retinopathy (DR), addressing unmet medical needs associated with intraocular administration of current therapies.
Multiple studies have demonstrated that PKC is an essential contributor to the retinal vascular permeability, VEGF induced retinal vascular leakage and angiogenesis, and inflammation present in diabetic eye diseases. MS-553 has the potential to effectively down-regulate abnormal vascular permeability, VEGF signaling, and inflammation in DME and DR.
MS-553 has a highly desired PK profile for an oral therapy of retinal diseases. Upon oral administration, MS-553 reaches high concentrations in the retinal tissue. Major improvements in selectivity, safety and PK enable MS-553 to address the significant shortcomings seen with previous pan-PKC inhibitors.
MS-553 demonstrated promising efficacy and safety in a phase 1b DME study.
Oncology: Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)
PKC-β is required for CLL cell survival and proliferation. It is downstream of Bruton's Tyrosine Kinase (BTK) in the B-cell receptor (BCR)-NF-κB signaling pathway. Targeting PKC-β may offer an effective therapeutic option for patients who have developed resistance to BTK inhibitors. In a phase 1/2 study, MS-553 has demonstrated clinical efficacy in patients with CLL/SLL who have developed multiple resistance mutations following treatment with BTK inhibitors.
Promising Clinical Data
We have obtained promising proof-of-activity data from ongoing clinical studies in patients with diabetic macular edema and chronic lymphocytic leukemia. Listed below are links to data from our DME and CLL trials presented at selected conferences.
The 2024 American Academy of Ophthalmology:
https://aao.scientificposters.com/epsAbstractAAO.cfm?id=1
The 2022 Annual Meeting of the America Society of Hematology:
Our Founders
CEO: Kai Zhang, MD, MBA
Dr. Zhang has been the CEO of MingSight Pharmaceuticals since its founding. Prior to MingSight, he had more than 10 years of experience in strategic planning and business development in the pharmaceutical industry. These included positions of increasing responsibility at Boehringer Ingelheim and ORA Clinical. He obtained his medical degree from Xiangya School of Medicine in China and his MBA from the Ross Business School of the University of Michigan.
CSO: Michael Niesman, PhD
Dr. Niesman is a PhD cell biologist. He spent 10 years in academia, specializing in ocular pharmacology, drug delivery and retinal cell biology before he moved to industry. While at Pfizer, he held multiple roles including global head of ophthalmology research and was a member of the Therapeutic Area Leadership Team in Ophthalmology. He co-founded MingSight with Dr. Zhang.
Contact Us
To contact us, please send a message to: info@mingsight.com
Our mailing address is:
MingSight Pharmaceuticals
PO Box 261208
San Diego, CA 92196-1208
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.